Neurology Flashcards
Multiple Sclerosis
Wide range of clinical symptoms and signs:
- Sensory, motor, cerebellar, cognitive
- Optic neuritis
- INO
- Acute partial myelopathy
- Lhermitte’s (electric shock sensation) and Uhthoff’s symptoms (elevated temperature impairs vision)
- Exercise-induced symptoms
Types of Multiple Sclerosis
Relapsing Remitting (RRMS)
- commonest type (>2/3 patients at onset)
- recovery between acute relapse episodes
Primary Progressive (PPMS) - progressive deterioration from disease onset without clear relapses and remissions.
Secondary Progressive (SPMS) - relapses/remissions then progressive deterioration.
MS Lesion Characteristics
Characteristic appearance and distribution of lesions:
- Periventricular, corpus callosum, centrum semiovale
- Radiating out from corpus callosum = Dawson’s fingers
- Brainstem, cerebellum
- Hyperintense on T2
- Hypointense on T1
Multiple Sclerosis Diagnosis
Clinical history and examination.
MRI.
Evoked potentials (EPs)
- VEP = visual EP (optic neuritis)
- SEP = somatosensory (limbs)
- BAER = brainstem EP = auditory pathways
Central Motor Conduction Time (CMCT)
- Motor pathways = corticospinal tracts to limbs
- MEPS = motor evoked potentials
Lumbar Puncture (LP) - oligoclonal bands +ve in CSF but NOT in serum, increased CSF IgG synthesis
Natalizumab
Alpha-4 integrin antagonist.
Selective adhesion molecule inhibitor.
MRI monitoring re. risk of PML
(Risk factors: JC virus positivity, prior immunosuppressive treatment, longer duration of Natalizumab treatment).
PML
Progressive multifocal leukoencephalopathy
Rapidly progressive demyelination in brain
Dementia, motor dysfunction, visual loss.
JC (polyoma virus) infection of oligodendrocytes.
Diagnosis JC virus in CSF via PCR.
MRI abnormal
Tx: immune reconstitution
Alemtuzumab
Humanised monoclonal Ab binds to CD52 (on B cells).
Fingolimod
Decreases the ability of lymphocytes to enter CNS by preventing the egress of lymphocytes from lymphatic tissues.
Reduces relapse rate and decreases new MRI lesions.
Potential cardiac SEs.
Neuromyelitis Optica (NMO)
a rare condition where the immune system damages the spinal cord and the nerves of the eyes (optic nerves).
Not typical MS. 90% recurrent events, may be severe, may be little improvement.
90% women
Aquaporin 4 NMO antibodies
Channelopathy, aquaporin 4 predominant water channel in CNS
Doesn’t respond to interferon or other MS therapies - treatment is immunosuppression (steroids or Rituximab)
Worse prognosis than MS
MOG Antibody Disease
MOG = Myelin Oligodendrocyte Glycoprotein disease
MS mimicker
ADEM presentation in children
Opticospinal (NMO type) in adolescents and adults -> optic neuritis and transverse myelitis.
INO
Typical feature of MS Due to lesion in MLF Loss or slowed ADDuction Horizontal nystagmus of ABDucting eye Lesion in MLF on side of decreased ADDuction
Temporal patterns of peripheral nerve disease
Acute: GBS, vasculitis, porphyria, infectious, toxic/drug
Subacute: toxic, nutritional, malignancy, paraneoplastic, metabolic
Chronic: inherited
Associated Phenomena Peripheral Neuropathies
Preceding infections or diarrhoea: - GBS (Campylobacter jejuni) Associated diseases: - Diabetes, renal, hepatic failure, thyroid dysfunction Medications: - Vinca alkaloids, cis platinum, amiodarone Toxins: - Lead, arsenic, thallium
Hereditary Motor and Sensory Neuropathy
HMSN1 = demyelinating, HMSN2 = axonal
HMSN1 (CMT 1)
- uniformly slowed nerve conduction velocities (<38m/s)
- dispersion and conduction block are rarely seen in comparison to acquired demyelinating neuropathies
- demyelination
Paraneoplastic Sensory Neuropathy
SCLC most commonly implicated
Sensory symptoms precede diagnosis of cancer by months
Pain and paraesthesiae - 1 limb, asymmetry, arms
Rapidly progressive (weeks)
All modalities of sensation affected
CSF: increased protein, pleocytosis, lymphocytes, OCBs positive, IgG ratio abnormal
NCS: decreased or absent SEPs and SNAPs, motor NCS and EMG may be normal
Antineuronal nuclear antibodies (ANNA) 1 = anti-Hu
Inclusion Body Myositis
Usually >50 years Commoner in men Proximal and distal Finger and wrist flexors Quadriceps Atrophy prominent Dysphagia in one third Poor response to steroids, immunoglobulin
Myasthenia Gravis
Symptoms: ptosis (not fixed, fatiguable), diplopia, limb weakness, neck weakness, SOB (emergency).
80% of MG has positive AChR AB, which are pathogenic, but levels correlate poorly with disease severity.
Association with hyperthyroidism, SLE, scleroderma and RA.
MuSK MG
20% have antibodies to muscle specific kinase
Thymus usually normal
HLA DR14-DQ5 association
Limb muscles often less affected
Progresses to severe facial and bulbar weakness, with atrophy of affected muscles
May require different treatment (Ritux)
MG Treatment
Acetyl-cholinesterase inhibitors: Pyridostigmine
Steroids
Steroid-sparing agents
Rituximab/Eculizumab
Myasthenic Crisis
Severe enough to endanger life. Diaphragm/intercostal muscle involvement. ICU. Treat infection if present. Increase Prednisolone. Plasma exchange or IVIG. Thromboprophylaxis.
LEMS
50% paraneoplastic - mainly SCLC.
Also non-SCLC.
Other 50% autoimmune disorders.
HLA B8 DR3 association.
IgG antibodies against voltage-gated calcium channels.
Weakness usually worse in lower limbs (proximal), not usually fatiguable.
Bulbar weakness and diplopia typically less persistent and severe than in MG.
Distal symmetrical sensory neuropathy.
Autonomic neuropathy (dry mouth/eyes and impotence).
Reflexes depressed, but potentiate as does power.
Treatment of LEMS
3-4 Diaminopyridine (potassium channel blocker)
Immunosuppression (as for MG)
Treat malignancy if present
Neurophysiological Diagnosis of NMJD
In LEMS and MG, at low frequency (1-5 Hz) there is a decrement with repetitive motor nerve stimulation.
In LEMS but not MG, at high frequency (20-50Hz) repetitive stimulation there is an incremental response.
NMDAR Encephalitis
F4:M1
50% of females have ovarian teratoma
Psychiatric features followed by movement disorder, drowsiness and seizures.